Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00750698 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib
A Phase 2 study, sponsored by Syndax Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 8
- Enrollment target
NCT00750698 is a Phase 2 study that was terminated before completion, run by Syndax Pharmaceuticals. The registered enrollment target is 8 participants.
The verdict
NCT00750698, a Phase 2 study, was terminated before completion, sponsored by Syndax Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 8 participants
- Enrollment target
Study Summary
To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.
Interventions
- DRUG Entinostat
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2008-08 |
| Est. Completion | 2010-06 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00750698
The ClinicalTrials.gov registry entry for NCT00750698 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Syndax Pharmaceuticals, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Entinostat is the first listed.
NCT00750698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00750698 about?
NCT00750698 is a clinical study titled "A Phase 2 Exploratory Study of Erlotinib and SNDX-275 in Participants With Non-small Cell Lung Carcinoma Who Are Progressing on Erlotinib". To evaluate the tumor responses to SNDX-275 (entinostat) in combination with continued erlotinib in participants with non-small Cell Lung Carcinoma (NSCLC) who are progressing on erlotinib.
What is the current status of trial NCT00750698?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 8 participants. The study started on 2008-08. Estimated completion is 2010-06.
What interventions are being tested in trial NCT00750698?
The interventions under investigation include: Entinostat (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT00750698?
This trial is sponsored by Syndax Pharmaceuticals, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.